Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Characterization and Clinical Outcomes of Severe Asthma Patients in Israel Treated With Benralizumab (SAIL-B)

NCT07218172 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT07218172
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07218172 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Characterization and Clinical Outcomes of Severe Asthma Patients in Israel Treated With Benralizumab (SAIL-B)
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Active, not recruiting
Start date
March 24, 2025
Completion date
November 30, 2026
Enrollment
197 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

severe asthma